Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data

Background: Risk stratification in the diagnostic pathway of prostate cancer (PCa) can be used to reduce biopsies and magnetic resonance imaging (MRI) scans, while maintaining the detection of clinically significant PCa (csPCa). The use of highly discriminating and well-calibrated models will genera...

Full description

Bibliographic Details
Main Authors: Sebastiaan Remmers, Veeru Kasivisvanathan, Jan F.M. Verbeek, Caroline M. Moore, Monique J. Roobol
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:European Urology Open Science
Subjects:
Clinical decision-making
Magnetic resonance imaging
Nomograms
Probability
Prostatic neoplasms
Risk stratification
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168321033796

Internet

http://www.sciencedirect.com/science/article/pii/S2666168321033796

Similar Items